The Effect of Rosiglitazone on Retinol Binding Protein 4 in Subjects of Impaired Glucose ToleranceHsieh, Chang-Hsun MD*; Hung, Yi-Jen MD*; Pei, Dee MD†; Wu, Chung-Ze MD‡; Hsiao, Fone-Ching MD*Author Information From the *Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan, Republic of China; †Department of Internal Medicine, Cardinal Tien Hospital, Medical School, Fu Jen Catholic University, Taipei, Taiwan, Republic of China; and ‡Division of Endocrinology and Metabolism, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, Republic of China. Supported by the grant from both the Tri-Service General Hospital and the cooperation research plan between National Defense Medical Center and Cardinal Tien Hospital (TSGH-C96–57 and NC97–01). Reprints: Chang-Hsun Hsieh, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, No 325, Sec 2, Chenggong Rd, 114 Nei-Hu, Taipei, Taiwan, Republic of China. E-mail: [email protected] The Endocrinologist: September/October 2010 - Volume 20 - Issue 5 - pp 250-253 doi: 10.1097/TEN.0b013e3181f661ec Buy Metrics Abstract Retinol-binding protein-4 (RBP4) is a novel adipokine, which is reported to be associated with obesity and insulin resistance (IR). We studied the effect of rosiglitazone (ROS), an insulin sensitizer, on the RBP4 plasma concentrations in subjects with impaired glucose tolerance (IGT). A single-blind, placebo-controlled comparison trial was conducted. A total of 26 IGT patients (mean age of 54 years) were enrolled; 14 received ROS (4 mg daily) and 12 received placebo. An enzyme immunoassay (EIA) was used to measure plasma RBP4 concentrations before and after therapy in both treatment groups. Plasma RBP4 concentrations were not associated with IR and cardiovascular risk factors with the exception of serum creatine levels. ROS therapy decreased RBP4 levels independent of IR, but associated with the changes in aspartate aminotransferase and triglyceride levels as well as basal serum RBB4 concentrations. In brief, plasma RBP4 concentrations in IGT subjects did not correlate with most cardiovascular risk factors and IR. However, treating IGT subjects with ROS resulted in decreased RBP4 levels independent of IR. © 2010 Lippincott Williams & Wilkins, Inc.